Carmen Espejo Ruiz I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies. Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Carmen Espejo Ruiz LinkedIn Twitter Orcid Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.
I obtained my degree in Biology from the University of Barcelona in 1998. I did my doctoral thesis at the Clinical Neuroimmunology Unit of the Hospital Universitari Vall d'Hebron, in which I studied the role of metallothioneins in the pathogenesis of multiple sclerosis, obtaining my PhD in Biology from the University of Barcelona in 2005. In 2008, I got a Miguel Servet contract that allowed me to establish myself as principal investigator of the Clinical Neuroimmunology group – Multiple Sclerosis Centre of Catalonia. Currently, I am a senior researcher at the Vall d'Hebron Research Institute and develop my scientific activity in the Clinical Neuroimmunology group - Center d'Esclerosi Múltiple de Catalunya. My main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim of developing new therapeutic strategies. I am currently focused on the role of immunosenescence in the pathogenesis of multiple sclerosis and the therapeutic potential of different senolytic drugs. I am also studying how the modification of the gut microbiota, through the administration of probiotics, could constitute a therapeutic tool in multiple sclerosis. Finally, I am carrying out a project that aims to induce immune tolerance, through the use of nanomedicine, with the aim of slowing down the autoimmune response in multiple sclerosis. I have more than 25 years of experience in animal models of multiple sclerosis and in the study of the immune response. At the Vall d'Hebron Research Institute, I am a member (since 2003) and the president (since 2006) of the Animal Experimentation Ethics Committee. I am also part of the Biosafety Committee (since 2015) and the Research Integrity Committee (since 2020). I have participated, as main or collaborating author, in 70 publications indexed in peer review journals. I have supervised eight doctoral theses and eight master's final projects. In addition, I participated as a teacher in various training activities, including the Master of Advanced Immunology at the Autonomous University of Barcelona and the University of Barcelona.
Projects Red Española de Esclerosis Múltiple (perteneciente a la Red CIEN C03/06): Desarrollo de marcadores biológicos y clínicos de la respuesta al tratamiento con Interferón beta en esclerosis múltiple. IP: Red Española de Esclerosis Múltiple (perteneciente a la Red CIEN C03/06): Desarrollo de marcadores biológicos y clínicos de la r Collaborators: Carlos Nos Llopis, Jordi Rio Izquierdo, Manuel Comabella Lopez, Carmen Espejo Ruiz Funding agency: Instituto de Salud Carlos III Funding: 714 Reference: PI052145 Duration: 01/01/2006 - 31/12/2006 UNiC-Unitat de Neuroimmunologia Clínica IP: UNiC-Unitat de Neuroimmunologia Clínica Collaborators: Carlos Nos Llopis, Jordi Rio Izquierdo, Manuel Comabella Lopez, UNiC-Unitat de Neuroimmunologia Clínica, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Mireia Castillo Juarez Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 35600 Reference: 2005SGR 01081 Duration: 01/01/2006 - 31/12/2008 Estudio de la subpoblación de linfocitos T CCR5+ en la etiopatogenia de la esclerosis múltiple (EM) y de la encefalomielitis autoinmune experimental (EAE). IP: Estudio de la subpoblación de linfocitos T CCR5+ en la etiopatogenia de la esclerosis múltiple (EM) y de la encefalomielitis aut Collaborators: Manuel Comabella Lopez, Carmen Espejo Ruiz Funding agency: Instituto de Salud Carlos III Funding: 47150 Reference: PI020160 Duration: 06/11/2002 - 06/11/2005 Inducción de tolerancia en la encefalitis autoinmune experimental mediante terapia génica IP: Jordi Barquinero Mañez Collaborators: Herena Eixarch Ahufinger, Carmen Espejo Ruiz Funding agency: Instituto de Salud Carlos III Funding: 71300 Reference: PI020205 Duration: 06/11/2002 - 06/11/2005 Pagination First page « Previous page ‹ … Page 3 Page 4 Page 5 Page 6 Current page 7
